

Whole-exome sequencing identifies mutated *PCK2* and *HUWE1* associated with carcinoma cell proliferation in a hepatocellular carcinoma patient

YAN-XUAN LIU^{1*}, SHU-FANG ZHANG^{2*}, YING-HUA JI³, SHENG-JU GUO⁴,
GENG-FU WANG⁵ and GUANG-WEN ZHANG⁶

¹Department of Genetic Disease, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100;

²Central Laboratory, Affiliated Haikou Hospital Xiangya School of Medicine Central South University
(Haikou Municipal People's Hospital), Haikou, Hainan 570208;

Departments of ³Oncology, ⁴Pharmaceutics, ⁵Anesthesiology and ⁶Infectious Diseases,
The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, P.R. China

Received April 23, 2012; Accepted July 20, 2012

DOI: 10.3892/ol.2012.825

Abstract. Hepatocellular carcinoma (HCC) is diagnosed in more than half a million individuals worldwide every year. It is often invasive and metastatic, resulting in a poor prognosis. Our knowledge of the genomic alterations implicated in HCC initiation and progression is fragmentary, and few molecular alterations unique to HCC are known. We performed whole-exome sequencing for a pleomorphic cell-type HCC tissue and matched normal tissue, and uncovered seven non-synonymous somatic variants in *SPATA21*, *PPCS*, *CDH12*, *OR1L3*, *PCK2*, *HUWE1* and *PHF16*. These variants were validated by PCR and sequencing, with the exception of that in *PPCS*. We further performed a bioinformatics analysis of the six validated variants. The results suggested that the function of the proteins of the three mutated genes, *PCK2*, *HUWE1* and *PHF16*, may be changed significantly. Among these genes, *PCK2*, within the insulin signaling pathway, and *HUWE1*, within the ubiquitin-mediated proteolysis pathway, may be essential for cell proliferation. These pathways are known to be important for hepatocarcinogenesis. Hence, we suggest that *PCK2* and *HUWE1* are associated with carcinoma cell proliferation in HCC.

Introduction

Hepatocellular carcinoma (HCC) is diagnosed in more than half a million individuals worldwide every year. Liver cancer is the fifth most common cancer in males and the seventh most common in females. Most of the burden of the disease (85%) is borne in developing countries, with the highest incidence rates reported in regions where infection with hepatitis B virus (HBV) is endemic, including Southeast Asia and sub-Saharan Africa. Additional risk factors for HCC are alcohol, toxins, including aflatoxin, hemochromatosis, α 1-antitrypsin deficiency and non-alcoholic fatty liver disease (NAFLD). HCC rarely occurs before the age of 40 years and reaches a peak at approximately 70 years of age. Rates of liver cancer among males are two to four times as high as the rates among females (1-5). Despite major efforts to improve the diagnosis and treatment of HCC, therapeutic options remain limited. Most patients, especially in Asia and sub-Saharan Africa, present at end stages of the disease or with underlying liver cirrhosis and consequently surgical options may no longer be indicated. Thus, there is a need for novel therapeutic agents and strategies. Despite its global significance, HCC is understudied compared with other major lethal types of cancer, and hence, our knowledge of the genomic alterations implicated in HCC initiation and progression is fragmentary. An improved understanding of the molecular genetic alterations specific to HCC may lead to the development of more efficient methods of prevention, early diagnosis and cure of this disease.

In this study, we carried out whole-exome sequencing using DNA obtained from HCC and matched normal tissue and found six previously unidentified variants in six genes. We further studied the molecular effects of these variants.

Materials and methods

Tissue and DNA preparation. HCC tissue was obtained from a 69-year-old male patient, who had chronic HBV infection

Correspondence to: Dr Yan-Xuan Liu, Department of Genetic Disease, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, Weihui 453100, P.R. China
E-mail: liuyx999@126.com

*Contributed equally

Key words: hepatocellular carcinoma, exome sequencing, somatic mutation

Table I. Summary of exome sequencing.

Item	HCC	Matched normal	Average
Total bases sequenced (Gb)	4.64	4.66	4.65
Mean depth of target region (-fold)	24	63	44
Percentage of the targeted bases which were covered at least once (%)	98.4	98.8	98.6
Percentage of the targeted bases which were covered sufficiently for variant calling (%)	87.6	96.6	92.1
Percentage of genes having >95% of their coding bases called (%)	70.4	83.5	77.0

HCC, hepatocellular carcinoma.

and lymph node metastasis. The matched normal tissue was obtained from a distance of 3-4 cm from the HCC. Informed consent for the research was obtained from the ethical committee of the Hospital. DNA of these tissues was extracted using the traditional phenol chloroform method.

Informed consent was obtained from the patient. The study was approved by the ethics committee of the First Affiliated Hospital of Xinxiang Medical University, Weihui, China.

Targeted sequence capture and sequencing. SeqCap EZ Human Exome Library version 2.0 (Roche Diagnostics, Mannheim, Germany; 44.1 Mb regions are covered by the probes. Cat no. 05860504001) was used for sequence capture according to the manufacturer's instructions. Genomic DNA (10 µg) was used to prepare the library with the Truseq DNA Sample Prep kit from Illumina (Illumina, San Diego, CA, USA; Cat. no. FC-121-1001). Sequencing was performed at a concentration of 12 pM on an Illumina Genome Analyzer IIx with paired-end 115-bp reads.

The genomic DNA library preparation, targeted sequence capture and massively parallel sequencing were completed by Guangzhou iGenomics Co., Ltd. (Guangzhou, China).

Alignment, variants calling and quality control. The software BWA (version 0.5.9) (6) was used to align the paired-end reads to the reference human genome (hg19). After the alignment, PCR duplications were removed using the SAMtools software package (version 0.1.16) (7). Candidate somatic variants were identified with the VarScan 2 software (version 2.2.8) and filtered by the accessory script (fpfilter.pl, version 1.01) with default parameters (8). To qualify the identified somatic variants, all candidate variants were subjected to manual review using the Integrative Genomics Viewer (9). Common variants were excluded by filtering known germ-line variants in Ensembl (version 64, <http://sep2011.archive.ensembl.org/index.html>) and an internal database composed of variants which occurred more than twice in 40 publicly available control genomes. A variant was noted if it was annotated as associated with a phenotype by Ensembl.

Bioinformatics analysis of non-synonymous somatic variants. The effects of the non-synonymous somatic variants were evaluated by bioinformatics analysis. The analysis of the chemical polarity and conservation, prediction of secondary structure and the domain of the proteins were performed. The conservation analysis was carried out by PhyloP (10) and

MutationTaster (11), the prediction of secondary structure was performed through Jpred (12) and the domain prediction was analyzed with UniProt (<http://www.uniprot.org>).

Results

Clinical information of the patient. A 69-year-old male patient was diagnosed with pleomorphic cell-type HCC with lymph node metastasis. The primary tumor was on the left lobe of the liver (10x8x6 cm in size) and showed invasive and septal cirrhosis with macro- and micronodules. It was a grade II to III HCC with prominent clear cell components. The results of serological tests for HBV showed that the tumor was positive for surface antigen, Anti-HBe (E) and core antibodies, indicating that the patient had chronic HBV infection.

Summary of exome sequencing. The mean total number of bases sequenced was 4.65 Gb. The mean depth of the target region was 44-fold. The mean percentage of the targeted bases which were covered at least once was 98.6%. The mean percentage of the targeted bases which were covered sufficiently for variant calling (coverage ≥5) was 92.1%. The mean percentage of genes having >95% of their coding bases called was 77.0%. The details of the quality are shown in Table I.

Discovery of somatic variants. Raw sequence data revealed 1514 candidate somatic single nucleotide variations (SNVs) and 158 candidate somatic small insertions and deletions (InDels) in the HCC tissue and 63047 candidate germ-line SNVs and 4513 InDels. A series of subsequent qualifications of these data narrowed down these variants into 27 tumor-specific SNVs and seven InDels (Fig. 1). We focused our analysis on the six non-synonymous substitutions and one frameshift mutation affecting the integrity of the open reading frame (ORF). These seven candidate variants were located in different genes, *SPATA21*, *PPCS*, *CDH12*, *ORIL3*, *PCK2*, *HUWE1* and *PHF16*. All the candidate variants were validated by PCR and sequencing, with the exception of a non-synonymous substitution in *PPCS*, which could not be distinguished from noise. Among these genes, *HUWE1* and *PHF16* were in the X chromosome. The details of the candidate variants are shown in Table II.

Bioinformatics analysis of validated variants. Six validated non-synonymous somatic variants were involved in the bioinformatics analysis, including five non-synonymous

Table II. Non-synonymous somatic variants identified in HCC by whole-exome sequencing.

Gene	Genomic locus ^a	Accession no.	Mutation	Protein	Function ^b
<i>SPATA21</i>	Chr1: 16748433	NM_198546	c.C68T	p.T23M	Calcium ion binding
<i>PPCS</i>	Chr1: 42922652	NM_024664	c.C416T	p.A139V	Phosphopantothenate - cysteine ligase activity
<i>CDH12</i>	Chr5: 22078699	NM_004061	c.G87C	p.Q29H	Calcium ion binding
<i>ORIL3</i>	Chr9: 125438256	NM_001005234	c.T848C	p.V283A	Odorant receptor
<i>PCK2</i>	Chr14: 24566276	NM_001018073	c.G205A	p.E69K	GTP binding/kinase activity
<i>HUWE1</i>	ChrX: 53596682	NM_031407	c.G6418A	p.A2140T	Acid - amino acid ligase activity/binding
<i>PHF16</i>	ChrX: 46887461	NM_001077445	c.642_643insA	p.G214fs	Zinc ion binding

^aCoordinates refer to the human reference genome hg19 release. ^bGene Ontology (<http://www.ebi.ac.uk/GOA/>). HCC, hepatocellular carcinoma.

Table III. Bioinformatics analysis of validated variants.

Gene	Mutation	Protein	Chemistry polarity	Secondary structure of protein	Domain	PhyloP value	Conservative species at protein level
<i>SPATA21</i>	c.C68T	p.T23M	Changed	Changed	Unknown	-2.074	NA
<i>CDH12</i>	c.G87C	p.Q29H	Changed	Changed	Unknown	2.801	Chimp, rhesus, cat, mouse, chicken
<i>ORIL3</i>	c.T848C	p.V283A	NA	NA	Known	1.866	Gorilla
<i>PCK2</i>	c.G205A	p.E69K	Changed	Changed	Unknown	5.208	Rhesus, cat, mouse, fugu, chicken, <i>Xenopus</i> , zebrafish, <i>C. elegans</i> , <i>Drosophila</i>
<i>HUWE1</i>	c.G6418A	p.A2140T	Changed	Changed	Unknown	5.451	Chimp, rhesus, mouse, zebrafish, fugu
<i>PHF16</i>	c.642_643insA	p.G214fs	Changed	Changed	Known	NA	NA




Figure 1. Processing of data obtained by whole-exome sequencing. The beginning of each box is the number of candidate somatic variants remaining after the step. SNV, single nucleotide variation; SNP, single nucleotide polymorphism; InDels, insertions and deletions; IGV, Integrative Genomics Viewer.

substitutions and one InDel. The chemical polarity of all the variants was changed, with the exception of the variation in *ORIL3*. Five variants would affect the secondary structure of

the protein and the variant of *ORIL3* would not. The frameshift variation in *PHF16*, located in the known domain, disturbed the gene structure. The results of conservation analysis indicated that the variants within *PCK2* and *HUWE1* may disturb the function of the protein encoded by these genes. The details of the analyzing of the candidate variants are shown in Table III.

Discussion

Using whole-exome sequencing, we identified seven non-synonymous somatic variants and validated six variants, which were previously unidentified in HCC. We further performed a bioinformatics analysis of the validated variants. The results suggest that the function of three mutated genes, *PCK2*, *HUWE1* and *PHF16*, may be markedly changed.

HCC is a major health problem worldwide (13). Despite its global significance, liver cancer is understudied compared to other major lethal types of cancer, and few known genetic influences on the development of HCC have been reported.

A number of studies in recent years have provided evidence that the *p53* tumor suppressor gene plays a major role in hepatocarcinogenesis (14). However, the frequency of *p53* variants and its mutation spectrum, with 75% missense variants, are exceptionally diverse in their position and nature, affecting over 200 codons scattered mainly

throughout the central portion of the gene (15). There were no candidate somatic variants found within *p53* in the patient of the present study.

The insulin-like growth factor (IGF) signaling system is an essential regulator of growth and development (16). The biological actions of the axis comprise a complex network of molecules whose main components are two high affinity mitogenic ligands: IGF1 and IGF2. The type 1 IGF receptor (IGF1R) has tyrosine kinase activity, the type 2 IGF receptor (IGF2R) is involved in the internalization and degradation of IGF2 and at least six high-affinity IGF-binding proteins (IGFBPs), which modulate the amount and bioactivity of locally available IGFs. Despite its role in normal physiology, the IGF axis is involved in the pathogenesis of several human malignancies, including breast, colon, prostate, lung and liver cancer (17). In HCC, the most frequently described aberrant feature concerning this pathway is overexpression of IGF2, which has been found in preneoplastic lesions (18). This mitogen, highly expressed during embryonic development, is markedly downregulated after birth by tight epigenetic regulation of the P2-P4 fetal promoters. Reactivation of IGF2 expression involves loss of specific imprinting and hypomethylation (19). Allelic losses of IGF2R has been detected in 60-70% of HCC cases, with inactivating variants in the remaining allele also reported (20). In addition, reduced expression of IGFBP-3 associated with promoter hypermethylation has been reported in human HCC samples (21). A recent study found aberrant activation of IGF1R in 21% of early stage hepatitis C-related HCC cases, and provided preclinical evidence of antineoplastic activity following IGF1R selective blockade using a monoclonal antibody (22). The potential role of the HBx viral protein as an inducer of IGF-IR expression has also been suggested (23). In the present study, the candidate gene *PCK2* is in the insulin signaling pathway. *PCK2* encodes a member of the phosphoenolpyruvate carboxykinase (GTP) family. The protein is a mitochondrial enzyme that catalyzes the conversion of oxaloacetate to phosphoenolpyruvate in the presence of GTP. A cytosolic form encoded by a different gene has also been characterized and is the key enzyme of gluconeogenesis in the liver. The encoded protein may serve a similar function, although it is constitutively expressed and not modulated by the hormones, including glucagon and insulin, that regulate the cytosolic form. Hill *et al* reported that the direct action of TNF to decrease the *PEPCK* transcription rate was confirmed *in vitro* with H-4-II-E Reuber hepatoma cells (24). The authors suggested that *PCK2* may be associated with hepatocarcinogenesis.

CTNNB1 and *AXIN1* variants are frequently found in HCC (25). Variants prevent β -catenin ubiquitination and subsequent degradation. Nuclear accumulation of β -catenin induces the transcription of several genes associated with cell differentiation and proliferation. In our study, the X-linked candidate gene *HUWE1* is in the ubiquitin-mediated proteolysis pathway. The mutated gene may prevent β -catenin ubiquitination and subsequent degradation, similar to *CTNNB1* and *AXIN1*. Notably, it is the X-linked gene which may contribute to the higher incidence of HCC in males.

In conclusion, we identified six genes with non-synonymous somatic variants in a HCC patient. Some of these genes

are involved in pathways associated with cell proliferation and differentiation, which is known to be important in hepatocarcinogenesis. Our results indicate that the insulin signaling and ubiquitin-mediated proteolysis pathways may be essential to HCC, and their relevant gene signature may be a target for new therapies in HCC. Larger sample sizes are needed to confirm or disprove our hypothesis.

Acknowledgements

We thank Dr Li Tong for the suggestions about the experiment design. This study was supported by the Provincial Education Science Foundation of Henan (2009A330004).

References

1. Motola-Kuba D, Zamora-Valdés D, Uribe M and Méndez-Sánchez N: Hepatocellular carcinoma. An overview. *Ann Hepatol* 5: 16-24, 2006.
2. Srivatanakul P, Sriplung H and Deerasamee S: Epidemiology of liver cancer: an overview. *Asian Pac J Cancer Prev* 5: 118-125, 2004.
3. McGlynn KA and London WT: Epidemiology and natural history of hepatocellular carcinoma. *Best Pract Res Clin Gastroenterol* 19: 3-23, 2005.
4. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. *J Clin Gastroenterol* 40 (Suppl 1): S5-S10, 2006.
5. Teo EK and Fock KM: Hepatocellular carcinoma: an Asian perspective. *Dig Dis* 19: 263-268, 2001.
6. Li H and Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 26: 589-595, 2010.
7. Li H, Handsaker B, Wysoker A, *et al*: 1000 Genome Project Data Processing Subgroup: The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25: 2078-2079, 2009.
8. Koboldt DC, Zhang Q, Larson DE, *et al*: VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res* 22: 568-576, 2012.
9. Robinson JT, Thorvaldsdóttir H, Winckler W, *et al*: Integrative genomics viewer. *Nat Biotechnol* 29: 24-26, 2011.
10. Pollard KS, Hubisz MJ, Rosenbloom KR and Siepel A: Detection of nonneutral substitution rates on mammalian phylogenies. *Genome Res* 20: 110-121, 2010.
11. Schwarz JM, Rödelberger C, Schuelke M and Seelow D: MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 7: 575-576, 2010.
12. Cole C, Barber JD and Barton GJ: The Jpred 3 secondary structure prediction server. *Nucleic Acids Res* 36: W197-W201, 2008.
13. Llovet JM, Di Bisceglie AM, Bruix J, *et al*: Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 100: 698-711, 2008.
14. Edamoto Y, Hara A, Biernat W, *et al*: Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. *Int J Cancer* 106: 334-341, 2003.
15. Hainaut P and Hollstein M: p53 and human cancer: the first ten thousand mutations. *Adv Cancer Res* 77: 81-137, 2000.
16. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. *Nat Rev Cancer* 8: 915-928, 2008.
17. Sachdev D and Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. *Mol Cancer Ther* 6: 1-12, 2007.
18. Laurent-Puig P and Zucman-Rossi J: Genetics of hepatocellular tumors. *Oncogene* 25: 3778-3786, 2006.
19. Tang SH, Yang DH, Huang W, Zhou HK, Lu XH and Ye G: Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. *Clin Cancer Res* 12: 4171-4177, 2006.
20. De Souza AT, Hankins GR, Washington MK, Orton TC and Jirtle RL: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. *Nat Genet* 11: 447-449, 1995.

21. Hanafusa T, Yumoto Y, Nouse K, *et al*: Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. *Cancer Lett* 176: 149-158, 2002.
22. Tovar V, Alsinet C, Villanueva A, *et al*: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. *J Hepatol* 52: 550-559, 2010.
23. Kim SO, Park JG and Lee YI: Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. *Cancer Res* 56: 3831-3836, 1996.
24. Hill MR and McCallum RE: Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice. *Infect Immun* 60: 4040-4050, 1992.
25. Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. *Semin Liver Dis* 27: 55-76, 2007.